AI Summary & Key Takeaways
AI InsightConclusion: As a result, we believe that patients who is under oral anticoagulant therapy, always carrying a risk of ischemic diseases and in this patient group risk factors are different from well known risk factors, so there will be a need for more work on this issue.
📌 3 Key Takeaways
Abstract
Objective: Many complications can occur while treating the ischemic diseases, also while under treatment some patients have recurrent ischemic diseases. In our study we aimed that to investigate dermographic characteristics, risk factors, and causes for patients, who has ischemic disease while under treatment of oral anticoagulant therapy for any reason and INR levels between 2-3. Method: The files of patients diagnosed with myocardial infarction, ischemic cerebro vascular disease and pulmonary embolism who applied to the emergency department between 01.01.2014 and 31.12.2015 were analyzed retrospectively. The data of patients with an INR value of 2-3 and using oral anticoagulants were found from the hospital automation system. The data obtained were evaluated with the SPSS 17 Statistical analysis program. Results: The INR value was determined in 2-3 of 452 pulmonary embolus patients, 24 of 1442 ischemic cerebrovascular patients, and 55 of 1263 myocardial infarction patients. 6 people from 55 patients with myocardial infarction, 3 people from 24 patients with pulmonary embolism and 3 people from 24 patients with stroke had the same disease before. The patients who diagnosed with pulmonary embolism, were seen less frequently received high Wells scores and big vessels embolism in the group with INR levels in treatment range. The patients diagnosed with stroke whose INR levels in treatment range, had atrial fibrillation more frequently. Congestive heart failure, atrial fibrillation and pulmonary embolism were found to be high risk factors in myocardial infarction patients with an INR value of 2-3. Conclusion: As a result, we believe that patients who is under oral anticoagulant therapy, always carrying a risk of ischemic diseases and in this patient group risk factors are different from well known risk factors, so there will be a need for more work on this issue.
Özet
Objective: Many complications can occur while treating the ischemic diseases, also while under treatment some patients have recurrent ischemic diseases. In our study we aimed that to investigate dermographic characteristics, risk factors, and causes for patients, who has ischemic disease while under treatment of oral anticoagulant therapy for any reason and INR levels between 2-3. Method: The files of patients diagnosed with myocardial infarction, ischemic cerebro vascular disease and pulmonary embolism who applied to the emergency department between 01.01.2014 and 31.12.2015 were analyzed retrospectively. The data of patients with an INR value of 2-3 and using oral anticoagulants were found from the hospital automation system. The data obtained were evaluated with the SPSS 17 Statistical analysis program. Results: The INR value was determined in 2-3 of 452 pulmonary embolus patients, 24 of 1442 ischemic cerebrovascular patients, and 55 of 1263 myocardial infarction patients. 6 people from 55 patients with myocardial infarction, 3 people from 24 patients with pulmonary embolism and 3 people from 24 patients with stroke had the same disease before. The patients who diagnosed with pulmonary embolism, were seen less frequently received high Wells scores and big vessels embolism in the group with INR levels in treatment range. The patients diagnosed with stroke whose INR levels in treatment range, had atrial fibrillation more frequently. Congestive heart failure, atrial fibrillation and pulmonary embolism were found to be high risk factors in myocardial infarction patients with an INR value of 2-3. Conclusion: As a result, we believe that patients who is under oral anticoagulant therapy, always carrying a risk of ischemic diseases and in this patient group risk factors are different from well known risk factors, so there will be a need for more work on this issue. Keywords: Oral anticoagulants; pulmonary embolism; ischemic stroke; myocardial infarction.